SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer - Quaterly Results

13 Aug 2025 Evaluate
A fair growth of 7.14% in the revenue at Rs. 6030.50 millions was reported in the June 2025 quarter as compared to Rs. 5628.60 millions during year-ago period.The company has announced a 27.23% increase in its profits to Rs . 1917.50  millions for the  quarter ended June 2025 compared to Rs. 1507.10 millions in the corresponding quarter in the previous year.Operating Profit saw a handsome growth to 2771.90 millions from 2193.30 millions in the quarter ended June 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 6030.50 5628.60 7.14 6030.50 5628.60 7.14 22813.50 21931.70 4.02
Other Income 671.70 418.40 60.54 671.70 418.40 60.54 1722.50 1805.10 -4.58
PBIDT 2771.90 2193.30 26.38 2771.90 2193.30 26.38 9124.80 8158.10 11.85
Interest 32.50 21.10 54.03 32.50 21.10 54.03 84.10 154.10 -45.43
PBDT 2739.40 2172.20 26.11 2739.40 2172.20 26.11 10768.80 8083.50 33.22
Depreciation 144.10 146.00 -1.30 144.10 146.00 -1.30 607.90 622.80 -2.39
PBT 2595.30 2026.20 28.09 2595.30 2026.20 28.09 10160.90 7460.70 36.19
TAX 677.80 519.10 30.57 677.80 519.10 30.57 2484.90 1947.40 27.60
Deferred Tax 3.90 -31.40 -112.42 3.90 -31.40 -112.42 -156.10 361.10 -143.23
PAT 1917.50 1507.10 27.23 1917.50 1507.10 27.23 7676.00 5513.30 39.23
Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00
PBIDTM(%) 45.96 38.97 17.96 45.96 38.97 17.96 40.00 37.20 7.53

Pfizer Share Price

4899.60 8.00 (0.16%)
21-Apr-2026 11:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.50
Dr. Reddys Lab 1221.45
Cipla 1230.00
Zydus Lifesciences 930.90
Lupin 2323.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×